Will I look back and regret not buying CSL shares at $237 today?

Is buying CSL shares today akin to catching a falling knife? Or will I regret not buying the healthcare stock at just over $237?

| More on:
Shot of a scientist recording his findings on a digital tablet.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

CSL Ltd (ASX: CSL) shares are up 0.4% in afternoon trade on Wednesday.

Shares in the S&P/ASX 200 Index (ASX: XJO) healthcare stock are currently changing hands for $237.35 apiece.

Despite that tick higher, the CSL share price remains down 15.8% since the opening bell on 3 January.

That compares to a 1.8% gain posted by the ASX 200 over this same time.

So, is buying CSL shares today akin to catching a falling knife?

Or will I regret not buying the healthcare stock at just over $237?

What's the outlook for CSL shares?

While the future is uncertain by definition, the majority of analysts are bullish on the one-year outlook for CSL shares.

Despite having a neutral rating on the stock, Goldman Sachs has a $296 12-month price target on its shares.

Citi's analysts are even more bullish, with a buy rating and a $325 price target. That represents a 37% upside from where CSL shares are trading at today.

Neither broker appears too concerned about the potential competition from Novo Nordisk's weight loss drug Ozempic to treat kidney disorders and other related illnesses, which could take a bite out of CSL's business.

CSL is still working to bring costs down to get its gross margins back up to pre-COVID levels.

On that front, CEO Paul McKenzie recently noted, "We are making genuine inroads, but there is more to do and it's just going to take some time."

More broadly, Janus Henderson Investors portfolio manager Andy Acker believes the healthcare sector's long-term outlook "appears stronger than ever".

"We think this is an attractive time to be investing in the healthcare sector," Acker said.

And last week CSL provided some promising FY 2024 guidance during the company's annual general meeting, though CSL shares dipped on the day.

The biotech stock is forecasting year on year revenue growth of 9% to 11%.

And FY 2024 guidance for net profit after tax and amortisation (NPATA) was forecast to come in between US$2.9 billion to US$3 billion on a constant currency basis. That translates to a year on year profit boost of 13% to 17%.

Time to buy?

So, will I regret not buying CSL shares at just over $237 today?

It appears that I might.

While I'm not jumping into the stock today, it's certainly high on my watchlist.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man slumps crankily over his morning coffee as it pours with rain outside.
Healthcare Shares

Why is this ASX 300 stock crashing 18% today?

Investors are rushing to the exits. But why? Let's look into things.

Read more »

Health professional working on his laptop.
Healthcare Shares

Are CSL shares at risk from the Trump tariffs?

How exposed are CSL shares to potential Trump medicinal tariffs?

Read more »

Donor donates blood in medical clinic. Beautiful European woman of 30 years sits in medical chair looking into camera and smiling.
Healthcare Shares

What did CSL have to say at Macquarie's 2025 conference?

Does this business have a healthy growth outlook?

Read more »

smiling health care workers in a medical setting
Healthcare Shares

Sonic Healthcare shares are down more than 40% since 2021. Will its AI initiative be the catalyst for a turnaround?

Could AI spark a recovery for this ASX healthcare stock?

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Why is this ASX All Ords stock jumping 7% today?

This stock is ending the week strongly. Let's find out what is getting investors excited.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Why is this ASX 200 stock crashing 30% today?

What's going with this stock? Let's find out why its shares are deep in the red.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 114% in a year, why is the Pro Medicus share price leaping higher again on Thursday?

Pro Medicus shares are back in form today and leaping ahead. Here’s why.

Read more »

Two doctors give the thumbs up to an x-ray
Healthcare Shares

Buying the dip: $10,000 invested in Pro Medicus shares on 7 April is now worth…

This healthcare stock has boomed over the past month. 

Read more »